Department of Thoracic Surgery, The Third People's Hospital of Zhengzhou, Zhengzhou 450000, China.
Contrast Media Mol Imaging. 2022 Oct 11;2022:2228744. doi: 10.1155/2022/2228744. eCollection 2022.
To investigate the need for and prognostic impact of gefitinib on the treatment of patients with early-stage epidermal growth factor receptor (EGFR) mutated non-small-cell lung cancer (NSCLC).
Clinical data of patients with stage IB-IIA non-squamous non-small-cell lung cancer admitted to our thoracic surgery department from January 2020 to January 2022 were collected, and a total of 94 cases were included, divided into 44 cases in the control group (EGFR mutation-negative) and 50 cases in the experimental group (EGFR mutation-positive (including those on medication (19 cases) and those not on medication (31 cases)) according to the outcome of EGFR mutation. To evaluate the necessity and prognostic effect of gefitinib in the treatment of NSCLC patients with early EGFR mutations.
The lung cancer recurrence rate in the experimental group (66.00%) was higher than that in the control group (40.91%), and the difference was statistically significant ( = 5.937, =0.015); in the subgroup analysis of the experimental group samples, the pharmacological intervention of gefitinib had a significant effect on lung cancer recurrence ( = 7.797, =0.005), and the proportion of lung cancer recurrence in patients not taking the drug (80.65%) was significantly higher than in the drug-taking group (42.11%); the median survival time was 53.6 months using EGFR mutation type as the study factor, with a statistically significant difference in change in 5-year survival rate for EGFR mutation type ( = 6.095, =0.047) and the lowest 5-year survival rate for subjects with EGFR mutation type Exon 20 T790M.
Patients with early gene drive positive lung adenocarcinoma are significantly more likely to recur and metastasise and have shorter survival times in the absence of pharmacological intervention.
探讨表皮生长因子受体（EGFR）突变的早期非小细胞肺癌（NSCLC）患者使用吉非替尼治疗的必要性和预后影响。
收集 2020 年 1 月至 2022 年 1 月我院胸外科收治的 IB-IIA 期非鳞状非小细胞肺癌患者的临床资料，共 94 例，根据 EGFR 突变结果分为对照组（EGFR 突变阴性）44 例和实验组（EGFR 突变阳性（包括用药组 19 例和未用药组 31 例）50 例。评估 EGFR 突变阳性早期 NSCLC 患者使用吉非替尼治疗的必要性和预后效果。
实验组（66.00%）的肺癌复发率高于对照组（40.91%），差异有统计学意义（ = 5.937， =0.015）；在实验组样本的亚组分析中，吉非替尼的药物干预对肺癌复发有显著影响（ = 7.797， =0.005），未服药患者（80.65%）的肺癌复发比例明显高于服药组（42.11%）；以 EGFR 突变类型为研究因素，中位生存时间为 53.6 个月，EGFR 突变类型 5 年生存率变化差异有统计学意义（ = 6.095， =0.047），EGFR 突变类型 Exon 20 T790M 患者的 5 年生存率最低。
无药物干预时，早期基因驱动阳性肺腺癌患者复发和转移的风险明显更高，生存时间更短。
